

# **PRODUCT MONOGRAPH**

## **Pr Vancomycin Hydrochloride for Injection**

(Vancomycin Hydrochloride USP)

500 mg/vial, 1 g/vial, and 10 g/vial Vancomycin

### **ANTIBIOTIC**

SteriMax Inc.  
1-2735 Matheson Blvd E  
Mississauga, ON  
L4W 4M8

Date of Preparation:  
August 20, 2013

Control No. 167324

## PRODUCT MONOGRAPH

### NAME OF DRUG

# **Pr Vancomycin Hydrochloride for Injection**

(Vancomycin Hydrochloride USP)

500 mg/vial, 1 g/vial and 10 g/vial Vancomycin

### THERAPEUTIC CLASSIFICATION

**Antibiotic**

### ACTIONS AND CLINICAL PHARMACOLOGY

The bactericidal action of vancomycin against most gram-positive bacteria results from the inhibition of the biosynthesis of peptidoglycan polymers during the second stage of cell wall synthesis in dividing organisms. This effect occurs at a site different from that of penicillins and cephalosporins. The cytoplasmic membrane composition may also be affected and membrane permeability altered. There is also evidence that vancomycin selectively inhibits RNA synthesis.

Vancomycin is a tricyclic glycopeptide antibiotic derived from *Amycolatopsis orientalis* (formerly *Nocardia orientalis*). It is primarily active against gram-positive organisms including staphylococci and streptococci. It is active against methicillin-resistant strains of *Staphylococcus aureus* and *Staphylococcus epidermidis*.

Vancomycin is poorly absorbed from the GI tract. It is given intravenously for therapy of systemic infections.

Following i.v. administration, vancomycin is widely distributed and inhibitory concentrations of vancomycin can be documented in the pericardial, pleural, ascetic and synovial fluids. Low concentrations of the drug may appear in CSF if meninges are inflamed. The volume of distribution for vancomycin ranges from 0.43 to 1.25 L/kg. At a concentration of 10 to 100 µg/mL *in vitro*, vancomycin is reportedly 52 to 60% bound to serum proteins.

#### **Pharmacokinetics**

In subjects with normal kidney function, multiple intravenous dosing of 1 g vancomycin (15 mg/kg), infused over 60 minutes, produces mean plasma concentrations of approximately 63 mg/L immediately at the completion of infusion, mean plasma concentrations of approximately 23 mg/L 2 hours after infusion, and mean plasma concentrations of approximately 8 mg/L 11 hours after the end of the infusion. Multiple dosing of 500 mg, infused over 30 minutes produces mean plasma concentrations of about 49 mg/L at the completion of the infusion, mean plasma concentrations of about 19 mg/L 2 hours after infusion and mean plasma concentrations of about 10 mg/L 6 hours after infusion. Plasma concentrations are slightly higher than those following a

single dose, as accumulation tends to occur after 2 to 3 days of i.v. administration at 6- or 12-hour intervals. The serum elimination half-life of vancomycin in adults with normal renal function has been reported to average 4 to 6 hours.

Vancomycin is excreted by the kidneys primarily by glomerular filtration; approximately 80 to 90% of the dose is excreted in the urine within 24 hours. Impairment of renal function results in delayed excretion and in high blood levels associated with an increase in drug toxicity. The total systemic and renal clearance may be reduced in the elderly.

### **INDICATIONS AND CLINICAL USE**

Vancomycin Hydrochloride for Injection, administered intravenously, is indicated for the treatment of severe or life-threatening staphylococcal infections in patients who cannot receive or have failed to respond to the penicillins or cephalosporins or who have infections with staphylococci resistant to other antibiotics, including methicillin.

Vancomycin alone has been used effectively in the treatment of staphylococcal endocarditis. Vancomycin has also been reported to be effective alone or in combination with an aminoglycoside for treatment of endocarditis, caused by *S. viridans* or *S. bovis*. For endocarditis caused by enterococci (*S. faecalis*), vancomycin has been reported to be effective only in combination with an aminoglycoside.

Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. It has been used successfully in combination with either rifampin, an aminoglycoside, or both, in early-onset prosthetic valve endocarditis caused by *S. epidermidis* or diphtheroids.

The effectiveness of vancomycin has been documented in other infections due to staphylococci, including osteomyelitis, pneumonia, septicemia and soft-tissue infections. Antibiotics are used as adjuncts to appropriate surgical measures when staphylococcal infections are localized and purulent.

Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.

Although no controlled clinical efficacy trials have been conducted, intravenous vancomycin has been suggested by the American Heart Association and the American Dental Association as prophylaxis against bacterial endocarditis in patients who are at risk in the following situations:

- a) In Dental, Oral or Upper Respiratory Tract Procedures  
As an alternate prophylactic regime in ampicillin/amoxicillin/penicillin-allergic patients considered high risk.
- b) In Genitourinary and Gastrointestinal Procedures  
In combination with gentamycin in ampicillin/amoxicillin/penicillin-allergic patients.

When selecting antibiotics for the prevention of bacterial endocarditis, the physician should read the full joint statement of the American Heart Association and the American Dental Association (*JAMA* 1990; 264: 2919-2922)

The parenteral form of vancomycin may be administered orally for the treatment of staphylococcal enterocolitis and antibiotic-associated pseudomembranous colitis produced by *Clostridium difficile*. **Parenteral administration of vancomycin is not effective for these indications. Vancomycin has not been shown to be effective by the oral route for the treatment of other types of infections. Vancomycin is not effective *in vitro* against gram-negative bacilli, mycobacteria or fungi.**

### **CONTRAINDICATIONS**

Vancomycin Hydrochloride for Injection is contraindicated in patients with known hypersensitivity to vancomycin hydrochloride.

### **WARNINGS**

Rapid bolus administration (e.g. over several minutes) of vancomycin may result in an exaggerated hypotension including shock and, rarely, cardiac arrest.

Vancomycin Hydrochloride for Injection should be administered in a dilute solution over a period of not less than 60 minutes to avoid rapid infusion-related reactions. Stopping the infusion usually results in a prompt cessation of these reactions (see **PRECAUTIONS and DOSAGE AND ADMINISTRATION**).

The dosage of Vancomycin Hydrochloride for Injection must be adjusted for patients with kidney dysfunction (see **PRECAUTIONS and DOSAGE AND ADMINISTRATION**).

Toxic serum levels can occur when vancomycin is given intravenously. Vancomycin is excreted by the kidney and blood levels increase markedly with decreased renal clearance. The risk of ototoxicity and nephrotoxicity appears appreciably increased during parenteral therapy by high blood concentrations or prolonged treatment in patients who have kidney dysfunction or underlying hearing loss or who are receiving concurrent therapy with another ototoxic agent such as an aminoglycoside. Vancomycin is poorly absorbed orally and toxic serum levels have not been reported from oral dosage.

Ototoxicity has occurred in patients receiving vancomycin. Reports of ototoxicity have been associated with serum vancomycin levels ranging from 40 to 80 µg/mL. Deafness may be preceded by tinnitus. Ototoxicity may be transient or permanent. The elderly are more susceptible to auditory damage. Experience with other antibiotics suggests that deafness may be progressive despite cessation of treatment.

Careful monitoring is required with concurrent and sequential use of other neurotoxic and/or nephrotoxic agents, particularly aminoglycoside antibiotics, loop diuretics, neuromuscular blocking agents, cephaloridine, polymyxin B, colistin, viomycin, paromomycin, bacitracin, amphotericin B and cisplatin.

If parenteral and oral vancomycin are administered concomitantly, an additive effect can occur. This should be taken into consideration when calculating the total dose. In these situations, careful monitoring of serum levels is recommended.

## PRECAUTIONS

Vancomycin Hydrochloride for Injection should be administered in a dilute solution over a period of not less than 60 minutes to avoid rapid infusion-related reactions. To minimize the risk of a hypotensive reaction, the patient's blood pressure should be monitored during the infusion. Stopping the infusion usually results in a prompt cessation of these reactions (see **DOSAGE AND ADMINISTRATION** and **ADVERSE REACTIONS**).

Vancomycin should be used with care in patients with renal insufficiency because of its ototoxicity and nephrotoxicity. The dose and/or dose intervals should be adjusted carefully. Vancomycin blood levels should be monitored and serial tests of renal and auditory functions administered if it is necessary to use vancomycin parenterally in patients with renal impairment and in individuals over the age of 60 (see **DOSAGE AND ADMINISTRATION**).

In patients with previous hearing loss, use of vancomycin should be avoided (if possible). If therapy is deemed essential, the dose of vancomycin should be monitored by periodic testing of auditory function and determination of drug levels in the blood.

Audiometric and renal function testing should be monitored in patients using other concurrent or sequential systemic or topical nephrotoxic or ototoxic drugs.

All patients receiving vancomycin should have periodic hematologic studies, urinalyses, liver and renal function tests.

Overgrowth of non-susceptible organisms may result with the use of vancomycin. If new infections due to bacteria or fungi appear during therapy with this product, appropriate measures should be taken, including withdrawal of vancomycin. In rare instances, there have been reports of antibiotic-associated pseudomembranous colitis due to *Clostridium difficile* developing in patients receiving anti-infective agents including intravenous vancomycin.

Reversible neutropenia has been reported in patients receiving vancomycin (see **ADVERSE REACTIONS**). Periodic monitoring of the leukocyte count should be performed in patients who will undergo prolonged therapy with vancomycin or those who are receiving concomitant drugs which may cause neutropenia.

**VANCOMYCIN SHOULD NEVER BE GIVEN INTRAMUSCULARLY.** Vancomycin is irritating to tissue and must be given by a secure intravenous route of administration. Pain, tenderness and necrosis occur with intramuscular injection of vancomycin or with inadvertent extravasation.

Pain and thrombophlebitis may occur in patients receiving vancomycin i.v. and can be severe. The frequency of severity of these infusion-related events can be minimized by administering the drug slowly as a dilute solution (2.5 to 5 mg/mL) and by rotating the sites of infusion. There have been reports that the frequency of infusion-related events (including hypotension, flushing, erythema, urticaria and pruritis) increases with concomitant administration of anesthetic agents. Infusion-related events may be minimized by the administration of vancomycin as a 60-minute infusion prior to anesthetic induction.

The safety and efficacy of administering Vancomycin Hydrochloride for Injection by the intrathecal (intralumbar and intraventricular) routes have not been evaluated.

Vancomycin is not indicated for intraperitoneal administration as safety and efficacy have not been determined.

Some patients with inflammatory disorders of the intestinal mucosa may have significant systemic absorption of oral vancomycin and may thus be at risk of developing adverse reactions associated with parenteral administration of vancomycin. This risk is greater in the presence of renal impairment. Total systemic and renal clearance of vancomycin are reduced in the elderly.

### **Use in the Elderly**

Since geriatric patients usually excrete vancomycin more slowly, they are at greater risk of vancomycin-induced ototoxicity and nephrotoxicity. Dosage adjustments are required to avoid excessive vancomycin serum concentrations (see **DOSAGE AND ADMINISTRATION**).

### **Use in Children**

In prematures, neonates and young infants, close monitoring of serum vancomycin concentrations may be warranted, as the renal immaturity of these patients may lead to increased serum concentrations of the drug. Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing in children. These adverse reactions may be minimized by administering vancomycin over at least one hour prior to induction of anesthesia (see **DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS**).

### **Use in Pregnancy**

Safe use of Vancomycin Hydrochloride for Injection during pregnancy has not yet been established. Vancomycin should be used during pregnancy only when clearly needed. In a controlled clinical study, vancomycin was administered to 10 pregnant women for serious staphylococcus infections complicating intravenous drug abuse. Vancomycin levels of 13.2 and 16.7 µg/mL were measured in cord blood of two patients. No sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted. Because the number of patients treated in this study was small and vancomycin administered only in the second and third trimester, it is not known whether vancomycin causes fetal harm.

### **Use in Nursing Mothers**

Vancomycin is excreted in human milk. Caution should therefore be exercised if vancomycin is administered to a nursing mother. Because of the potential for serious adverse events, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of vancomycin to the woman.

### **Burn Patients**

Burn patients reportedly have higher total body clearance rates for vancomycin and may thus require more frequent and higher doses. When vancomycin is used in these patients, dosage individualization and close monitoring are recommended.

### **ADVERSE REACTIONS**

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)

Call toll-free at 1-866-234-2345

Complete a Canada Vigilance Reporting Form and:

- Fax toll-free to 1-866-678-6789, or
- Mail to: Canada Vigilance Program

Health Canada

Postal Locator 0701C

Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

### **Infusion-Related Events**

Rapid administration of Vancomycin Hydrochloride for Injection may be associated with anaphylactoid reactions including hypotension, wheezing, dyspnea and pruritus. Additionally, flushing of the skin over the neck and shoulder area (“red neck”) with transitory fine rash including urticaria and a throbbing type of pain in the muscles of the back and neck has been reported during rapid administration. These reactions usually resolve within 20 to 30 minutes but may persist for several hours. Infusion-related events may be minimized or avoided by slower administration (see **DOSAGE AND ADMINISTRATION**).

### **Nephrotoxicity**

Renal failure has been reported in patients treated with vancomycin, principally manifested by increased serum creatinine or BUN, particularly in patients given large doses. Most of these have occurred in patients who were given aminoglycosides concomitantly or who had pre-existing kidney dysfunction. When vancomycin was discontinued, azotemia resolved in most patients. Rare cases of interstitial nephritis have been reported in patients treated with vancomycin.

### **Ototoxicity**

There have been reports of hearing loss in patients receiving vancomycin. Most of these patients also had kidney dysfunction, pre-existing hearing loss or concomitant treatment with an ototoxic drug. Vertigo, dizziness and tinnitus have been reported rarely.

### **Hematopoietic**

Reversible neutropenia, usually starting one week or more after onset of therapy with vancomycin or after a total dose of more than 25 g, has been reported. Neutropenia appeared to be, in several patients, promptly reversible when vancomycin was discontinued. Thrombocytopenia has rarely been reported. Reversible agranulocytosis (granulocyte count less than  $500/\text{mm}^3$ ) has been reported rarely.

### **Phlebitis**

Inflammation at the injection site and thrombophlebitis have been reported.

### **Miscellaneous**

Anaphylaxis, nausea, chills, drug fever, urticaria, eosinophilia, and rashes including exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis and rare cases of vasculitis have been associated with the administration of vancomycin.

## **SYMPTOMS AND TREATMENT OF OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

Supportive treatment is advised with maintenance of glomerular filtration. Plasma concentrations of vancomycin are reported to be minimally affected by conventional hemodialysis. Increased vancomycin clearance has been reported with highly permeable membranes used in high-flux hemodialysis. At 4-6 hours following the onset of high-flux hemodialysis, steady state concentrations of vancomycin may be reduced by 10-15% of the pre-dialysis concentrations. Peritoneal dialysis, although it may decrease concentrations, does not remove significant amounts.

Hemofiltration and hemoperfusion with polysulfone resin has been reported to result in increased clearance of vancomycin.



## DOSAGE AND ADMINISTRATION

### DOSAGE

Solutions of Vancomycin Hydrochloride for Injection reconstituted with Sterile Water for Injection contain no bacteriostat and are intended for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded. Further dilution is required before use (see **PHARMACEUTICAL INFORMATION – Reconstitution**).

EACH DOSE SHOULD BE ADMINISTERED AT A RATE OF NO MORE THAN 10 mg/min OR OVER A PERIOD OF AT LEAST 60 MINUTES.

Within 48 to 72 hours, most patients with infections susceptible to vancomycin show a therapeutic response. The type and severity of the infection and the clinical response of the patient determine the duration of therapy.

#### Intravenous Dosage

##### Adults with Normal Renal Function

The usual daily intravenous dose is 2 g divided either as 500 mg every 6 hours or 1 g every 12 hours. Each dose should be administered over a period of at least 60 minutes. Other patient factors, such as age or obesity, may call for modification of the usual daily dose.

##### Adults with Impaired Renal Function

Dosage adjustment must be made in patients with impaired renal function to avoid toxic serum levels. Since accumulation in such patients has been reported to occur over several weeks of treatment, serum levels should be checked regularly. Because of decreasing renal function in the elderly, dosage reduction may be necessary.

Measurement of vancomycin serum concentrations can be helpful in optimizing therapy, especially in seriously ill patients with changing renal function.

For most patients with renal impairment or the elderly, the dosage can be calculated by using the following table if creatinine clearance is known. The dosage of Vancomycin Hydrochloride for Injection per day in mg is about 15 times the glomerular filtration rate in mL/min (see Table 1).

Table 1  
Vancomycin Dosage in Patients with Impaired Renal Function\*  
(adapted from Moellering et al., 1981<sup>1</sup>)

| Creatinine Clearance (mL/min)  | Vancomycin Hydrochloride for Injection<br>Dose (mg/24 hrs) |
|--|--|
| 100  | 1545   |
| 90   | 1390   |
| 80   | 1235   |
| 70   | 1080   |
| 60   | 925  |
| 50   | 770  |
| 40   | 620  |
| 30   | 465  |
| 20   | 310  |
| 10   | 155  |
| * The initial dose should be no less than 15 mg/kg even in patients with mild to moderate renal insufficiency                              |  |
| Moellering RC et al.: Vancomycin therapy in patients with impaired renal function: a monogram for dosage. <i>Ann Int Med</i> 1981; 94: 343 |  |

This table is not valid for functionally anephric patients on dialysis. For such patients, an initial dose of 15 mg/kg body weight should be given in order to achieve prompt therapeutic serum concentrations. The dose required to maintain stable serum levels is 1.9 mg/kg/24 hr. Since individual maintenance doses of 250 to 1000 mg are convenient, one dose may be given every several days rather than on a daily basis in patients with marked renal impairment.

When only the serum creatinine concentration is known, the following formula (based on sex, weight and age of the patient) may be used to estimate creatinine clearance. Calculated creatinine clearances (mL/min) are only estimates.

|   |   |
|---|---|
| Estimated creatinine clearances<br>for<br>Men | $\frac{\text{Weight (kg)} \times (140 - \text{age in years})}{72 \times \text{serum creatinine concentration (mg/dL)}}$ |
| for:<br>Women                                 | 0.85 x above value  |

Serum creatinine must represent a steady state of renal function; otherwise the estimated value for clearance is not valid. Such a calculated clearance is an over-estimate of the actual clearance in patients with conditions:

- 1) characterized by decreasing renal function, such as shock, severe heart failure, or oliguria;
- 2) in which a normal relationship between muscle mass and total body weight is not present, such as in obese patients or those with liver disease, edema, or ascites; and

3) accompanied by debilitation, malnutrition, or inactivity.

### **Pediatric Use:**

The following dosage schedule has been used. Infusion should be over a period of at least 60 minutes and can be incorporated into the child's 24-hour fluid requirement.

### **Neonates:**

In neonates, an initial dose of 15 mg/kg is suggested, followed by 10 mg/kg every 12 hours for neonates in the first week of life, and every 8 hours thereafter up to the age of one month. Close monitoring of serum concentrations of vancomycin may be warranted in these patients.

### **Infants and Children:**

The usual intravenous dosage of vancomycin is 10 mg/kg/dose given every six hours. The majority of patients with infections caused by organisms susceptible to the antibiotic show a therapeutic response by 48 to 72 hours. The total duration of therapy is determined by the type and severity of the infection and the clinical response of the patient.

### **Oral Dosage**

#### **Adults**

The usual daily dose for antibiotic-associated pseudomembranous colitis caused by *C. difficile* and/or staphylococcal enterocolitis is 125 to 500 mg orally every 6 to 8 hours for 7 to 10 days.

#### **Children**

The usual daily dosage is approximately 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The total daily dose should not exceed 2 g.

## **ADMINISTRATION**

Intermittent infusion is the recommended method of administration.

### **Intermittent Intravenous Infusion:**

The reconstituted solution must be further diluted with 100 to 200 mL normal saline or 5% Dextrose in Sterile Distilled Water for Injection (D5-W). This should be infused over a period of at least 60 minutes (see **PHARMACEUTICAL INFORMATION – Reconstitution**).

### **Continuous Intravenous Infusion**

Continuous intravenous infusion should be used only when intermittent infusion is not practical.

**Note:** Infusion-related events are related to both concentration and rate of administration of vancomycin. A concentration of no more than 5 mg/mL and rates of no more than 10 mg/min are recommended in adults (see age-specific recommendations). In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used; use of such higher

concentrations may increase risk of infusion-related events. Infusion-related events may occur, however, at any rate or concentration.

### Oral Administration

The contents of the i.v. vial (500 mg) may be diluted in 30 mL of water and given to the patient to drink, or the diluted material may be administered via a nasogastric tube.


## PHARMACEUTICAL INFORMATION

### Drug Substance

**Proper Name:** Vancomycin hydrochloride

**Chemical Name:** (S<sub>a</sub>)-(3S,6R,7R,22R,23S,26S,36R,38aR)-44-[[[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl- $\alpha$ -L-lyxo-hexopyranosyl)- $\beta$ -D-glucopyranosyl]oxy]-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-[(2R)-4-methyl-2-(methylamino)valeramido]-2,5,24,38,39-pentaoxo-22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9]oxadiazacyclohexadecino[4,5-*m*]-[10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid, monohydrochloride.

### Structural formula:



.HCl

**Molecular Formula:** C<sub>66</sub>H<sub>75</sub>Cl<sub>2</sub>N<sub>9</sub>O<sub>24</sub>.HCl

**Molecular Weight:** 1485.73

**Description:**

Vancomycin hydrochloride is a tricyclic glycopeptide antibiotic. It is an off-white, free-flowing powder, very soluble in water at pH 4, moderately soluble in aqueous methanol, but insoluble in higher alcohols, acetone or ether. The melting point is 105°C.

**Composition**

Sterile vials contain vancomycin hydrochloride equivalent to either 500 mg, 1 g, or 10 g of vancomycin base as a lyophilized plug. When reconstituted in Sterile Water for Injection, USP, it forms a clear solution with pH of 4.0 (2.5 to 4.5). May contain hydrochloric acid and/or sodium hydroxide for pH adjustment.

**Reconstitution**

**Flip-Top Vial**

Solution for Reconstitution: Sterile Water for Injection, USP

Reconstitute as follows (see Table 2):

| <b>Table 2<br/>Reconstitution</b> |                                   |                                 |                                 |
|-----------------------------------|-----------------------------------|---------------------------------|---------------------------------|
| <b>Flip-Top Vial Sizes</b>        | <b>Volume to be Added to Vial</b> | <b>Approx. available volume</b> | <b>Vancomycin Concentration</b> |
| 500 mg                            | 10 mL                             | 10.3 mL                         | 50 mg/mL                        |
| 1 g                               | 20 mL                             | 20.6 mL                         | 50 mg/mL                        |
| 5 g                               | 100 mL                            | 103.0 mL                        | 50 mg/mL                        |
| 10 g                              | 95 mL                             | 97.85 mL                        | 100 mg/mL                       |

**Note: FURTHER DILUTION REQUIRED**

**For Intermittent Intravenous Infusion**

500 mg vial: Reconstituted solutions must be diluted with at least 100 mL of 0.9% Sodium Chloride Injection or 5% Dextrose in Sterile Water for Injection.

1 g vial: Reconstituted solutions must be diluted with at least 200 mL of 0.9% Sodium Chloride Injection or 5% Dextrose in Sterile Water for Injection.

5 g vial: Further dilution of the reconstituted solution is required. The 5 g vial is a Pharmacy Bulk Package intended for pharmacy use only.

10 g vial: Further dilution of the reconstituted solution is required. The 10 g vial is a Pharmacy Bulk Package intended for pharmacy use only.

## **Pharmacy Bulk Package**

**The availability of the Pharmacy Bulk Package is restricted to hospitals with a recognized intravenous admixture program.**

### **Directions for Dispensing from (Pharmacy Bulk Package – Not for Direct Infusion):**

Pharmacy Bulk Package is a **single-use** vial for pharmacy use only. The 5 g and 10 g vials should be suspended as a unit in a laminar flow hood. Entry into the vial must be made with a sterile dispensing device and contents dispensed in aliquots using aseptic technique (see **DOSAGE AND ADMINISTRATION**). Use of syringe/needle is not recommended as it may cause leakage. **Any unused portion of the reconstituted stock solution should be discarded within 8 hours after initial entry.**

### **For Continuous Intravenous Infusion**

The vials reconstituted according to the above table should be further diluted to the desired volume with one of the following i.v. solutions:

- 5% Dextrose Injection
- 3.3% Dextrose Injection and 0.3% Sodium Chloride Injection
- Lactated Ringer's Injection
- 0.9% sodium Chloride Injection

A concentration of no greater than 5 mg/mL is recommended.

### **Stability and Storage Recommendations**

#### Dry Powder

Vancomycin hydrochloride powder should be stored between 15° and 25°C.

#### Solutions

Reconstituted solutions and further diluted infusion mixtures should be used within 24 hours if kept at room temperature or within 72 hours if stored under refrigeration (5°C). If prepared in a facility with a recognized parenteral intravenous admixture program, such mixtures may be kept up to 96 hours if stored under refrigeration (5°C).

**NOTE:** As with all parenteral drug products, intravenous admixtures should be inspected visually for clarity, particulate matter, precipitation, discoloration and leakage prior to administration whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should not be used. Discard unused portion.

## Incompatibility

Vancomycin solution has a low pH and may cause physical instability of other compounds.

Some of the specific substances found to be incompatible are aminophylline, chloramphenicol sodium succinate, chlorthiazide sodium, dexamethasone sodium phosphate, diphenylhydantoin sodium, methicillin sodium, vitamin B<sub>12</sub> complex with C, sulfisoxazole diethanolamine, heparin sodium, potassium penicillin G, hydrocortisone sodium succinate, amobarbital sodium, nitrofurantoin sodium, pentobarbital sodium, phenobarbital sodium, secobarbital sodium, sodium bicarbonate, sulfadiazine sodium, and warfarin sodium.

**NOTE:** Common flavouring syrups have been added to the solution to improve the taste for oral administration. There is no information to indicate that the potency or efficacy of the drug is affected by the addition of these agents.

## **AVAILABILITY OF DOSAGE FORMS**

Vancomycin Hydrochloride for Injection is supplied as a sterile, lyophilized powder of vancomycin hydrochloride equivalent to:

- 500 mg vancomycin base in 10 or 20 mL single-dose glass vials, closed with rubber stoppers and flip-off caps. Packages of 10 (20 mL vials) or 25 (10 mL vials)
- 1 g vancomycin base in 20 mL single-dose glass vials, closed with rubber stoppers and flip-top caps. Packages of 10.
- 10 g vancomycin base in 100 mL single-use glass vials, closed with rubber stoppers and flip-top caps. Vials are individually packaged.\*

\* The 10 g vials have labels with integrated hangers which can be peeled back and used to suspend the bottle as a unit in a laminar air flow hood.

## MICROBIOLOGY

### Overview

Cross-resistance has not been demonstrated between vancomycin hydrochloride and other classes of antibiotics. Laboratory-induced resistance has been reported to occur in a slow stepwise fashion. The development of resistance to vancomycin by staphylococci has not been reported in clinical use. Changes in pH or the presence of serum does not significantly alter vancomycin's activity.

Vancomycin is active *in vitro* against staphylococci, including *Staphylococcus aureus* and *Staphylococcus epidermidis* (including heterogeneous methicillin-resistant strains); Streptococci including *Streptococcus pyogenes*, *Streptococcus pneumoniae* (including penicillin-resistant strains); *Streptococcus agalactiae*, the viridans group, *Streptococcus bovis*, and enterococci (e.g. *Streptococcus faecalis*); Clostridium species including *Clostridium difficile*, (e.g. toxigenic strains implicated in pseudomembranous enterocolitis); and Diphtheroids. Other organisms that are susceptible to vancomycin *in vitro* include *Listeria monocytogenes*, Lactobacillus species, Actinomyces species, Clostridium species and Bacillus species.

**Note:** Many strains of streptococci, staphylococci, *C. difficile* and other gram-positive bacteria are susceptible *in vitro* to concentrations of 0.5 to 5 mg/L. Staphylococci are generally susceptible to less than 5 mg/L of vancomycin hydrochloride, but a small proportion of *S. aureus* strains require 10 to 20 mg/L for inhibition.

Vancomycin is not effective *in vitro* against Gram-negatives bacilli, mycobacteria or fungi.

Susceptibility data showing the antibacterial activity of vancomycin are compiled in Table 3.

**Table 3**

***In Vitro Antibacterial Activity of Vancomycin***

| Organism   | Number of Isolates | MIC <sub>50</sub> (mg/L) | MIC <sub>90</sub> (mg/L) |
|--|--------------------|--------------------------|--------------------------|
| <i>S. aureus</i>                                 | 90                 | 1.6                      | 3.1                      |
| <i>S. aureus</i>                                 | 22                 | 0.7                      | 0.9                      |
| <i>S. aureus</i><br>(methicillin-resistant)      | 22                 | 1.6                      | 3.1                      |
| <i>S. aureus</i> (methicillin-resistant)         | 26                 | 0.4                      | 0.4                      |
| <i>S. epidermidis</i>                            | 50                 | 1.6                      | 6.3                      |
| <i>S. epidermidis</i><br>(methicillin-resistant) | 27                 | 1.6                      | 3.1                      |
| <i>S. epidermidis</i><br>(methicillin-resistant) | 25                 | 2.0                      | 4.0                      |
| Coagulase-negative Staphylococci                 | 200                | 2.0                      | 4.0                      |
| <i>Streptococcus pyogenes</i>                    | 110                | 0.5                      | 0.5                      |
| <i>Streptococcus pneumoniae</i>                  | 74                 | 0.5                      | 0.5                      |



|  |     |            |     |
|--|-----|------------|-----|
| <i>S. pneumoniae</i> (penicillin-resistant)  | 10  | 1.0        | 2.0 |
| <i>S. bovis</i>                              | 100 | 0.25       | 0.5 |
| <i>Streptococcus mutans</i> (viridans group) | 82  | 0.8        | 1.6 |
| <i>Streptococcus agalactiae</i> (Group B)    | 148 | 1.6        | 1.6 |
| <i>Streptococcus faecalis</i>                | 347 | 1.6        | 1.6 |
| Diphtheroids (including CDC-JK strains)      | 98  | 0.8        | 0.8 |
| <i>Listeria sp</i>                           | 26  | 0.8        | 1.6 |
| <i>Clostridium difficile</i>                 | 78  | 1.0        | 2.0 |
| <i>Clostridium sp</i>                        | 14  | 0.8        | 3.1 |
| <i>Lactobacillus sp</i>                      | 3   | 1.25       | --- |
| <i>Actinomyces sp</i>                        | 58  | 5.0        | --- |
| <i>Bacillus cereus</i>                       | 10  | 2.2 (mean) | --- |
|  |     |            |     |

### **Synergy**

The combination of vancomycin and an aminoglycoside acts synergistically *in vitro* against many strains of *S. aureus*, nonenterococcal group D Streptococci, enterococci and Streptococcus species (viridans group).

### **Susceptibility Testing/Diffusion and Dilution Techniques**

The following recommendations are based on current NCCLS antimicrobial susceptibility testing standards M2-A5, M7-A3 and M2-A5 for the disk diffusion and dilution techniques. The performance standards for the susceptibility testing are based on the tables found in the NCCLS document M100-S5.

The standard single disc susceptibility test (using 30 µg vancomycin hydrochloride disc) and the dilution susceptibility test for gram positive organisms other than *S. pneumoniae* and enterococci should be interpreted according to the criteria in Table 4.

| <b>Table 4</b><br><b>Criteria for the interpretation of standard single disc and dilution susceptibility tests</b> |                           |   |
|--|---------------------------|---|
|  | <b>Zone Diameter (mm)</b> | <b>Appropriate MIC Correlate (mg/L)</b> |
| Susceptible  | ≥ 12                      | ≤ 4                                     |
| Intermediate   | 10 – 11                   | 4 to < 16                               |
| Resistant  | ≤ 9                       | ≥ 16                                    |
| <b>Note:</b> These criteria and the definition are in agreement with NCCLS. Order Code M100-55.                    |                           |   |

Table 5 and Table 6 provide the criteria for the interpretation of standard disc and dilution susceptibility tests for *S. pneumoniae* and for enterococci, respectively.

| <b>Table 5</b><br><b>Criteria for the interpretation of standard disc and dilution susceptibility tests for <i>S. pneumoniae</i></b>               |                           |   |
|--|---------------------------|---|
|  | <b>Zone Diameter (mm)</b> | <b>Appropriate MIC Correlate (mg/L)</b> |
| Susceptible  | ≥ 17                      | ≤ 1                                     |
| <b>Note:</b> Strains yielding results suggestive of a “Nonsusceptible” category should be submitted to a reference laboratory for further testing. |                           |   |

| <b>Table 6</b><br><b>Criteria for the interpretation of standard disc and dilution susceptibility tests for enterococci</b> |                           |   |
|---|---------------------------|---|
|   | <b>Zone Diameter (mm)</b> | <b>Appropriate MIC Correlate (mg/L)</b> |
| Susceptible   | ≥ 17                      | ≤ 4                                     |
| Intermediate  | 15 -16                    | --                                      |
| Resistant   | ≤ 14                      | ≥ 32                                    |

A report of “Susceptible” indicates that the test organism is likely to respond to therapy.

A report of “Intermediate” indicates that the organisms in this category are likely to respond if the infection is confined to tissues or fluids in which high antibiotic concentrations are attained.

A report of “Resistant” indicates that achievable drug concentrations are unlikely to be inhibitory and other therapy should be selected.

### **Standardized Diffusion Techniques**

Standardized procedures require the use of laboratory control organisms. The 30 µg vancomycin hydrochloride disk should give zone diameters as presented in Table 7.

| <b>Table 7</b><br><b>Zone Diameter for the 30 µg vancomycin disk</b> |            |                           |
|--|------------|---------------------------|
| <b>Organisms</b>   |            | <b>Zone Diameter (mm)</b> |
| <i>S. aureus</i>   | ATCC 25923 | 15 - 19                   |

### **Standardized Dilution Techniques**

As with standardized diffusion techniques, dilution procedures require the use of laboratory control organisms. Standard vancomycin powder should provide MIC values presented in Table 8.

| Table 8<br>Standard vancomycin powder MIC values |           |            |
|--|-----------|------------|
| Organisms  |           | MIC (mg/L) |
| <i>S. aureus</i>                                 | ATCC29213 | 0.5 to 2.0 |
| <i>E. faecalis</i>                               | ATCC29212 | 1.0 to 4.0 |

## PHARMACOLOGY

### HUMAN

#### Pharmacodynamics

Vancomycin is bactericidal and appears to bind to the bacterial cell wall causing blockage of glycopeptide polymerization. This effect occurs at a site different from that affected by the penicillins and produces immediate inhibition of cell wall synthesis and secondary damage to the cytoplasmic membrane.

#### Pharmacokinetics

In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 gm/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mg/L immediately at the completion of the infusion, mean plasma concentrations of approximately 23 mg/L 2 hours after the infusion and mean plasma concentrations of approximately 8 mg/L 11 hours after the end of the infusion. Multiple dosing of 500 mg infused over 30 minutes produces mean plasma concentrations of about 49 mg/L at the completion of the infusion, mean plasma concentrations of about 19 mg/L 2 hours after infusion, and mean plasma concentrations of about 10 mg/L 6 hours after infusion. Plasma concentrations are slightly higher than those following single dose as accumulation tends to occur after 2 to 3 days of I.V. administration at 6- or 12-hour intervals.

In normal subjects, the elimination half-life of vancomycin from plasma ranges from 4 to 6 hours. About 80 to 90% of an administered dose of vancomycin is excreted in urine by glomerular filtration in the first 24 hours. Excretion of vancomycin is slowed by renal dysfunction. The average half-life of elimination is 7.5 days in anephric patients.

There is no apparent metabolism of the drug. Vancomycin is not effectively removed by either hemodialysis or peritoneal dialysis. Plasma concentrations of vancomycin are reported to be minimally affected by conventional hemodialysis. Increased vancomycin clearance has been reported with highly permeable membranes used in high-flux hemodialysis. At 4-6 hours following the onset of high-flux hemodialysis, steady state concentrations of vancomycin may be reduced by 10-15% of the pre-dialysis concentrations. Peritoneal dialysis, although it may decrease concentrations, does not remove significant amounts. Reduction in total systemic and renal clearance may be observed in the elderly.

Following oral administration of vancomycin to normal subjects, serum levels are undetectable but trace amounts are recovered in the urine. Vancomycin is excreted by the fecal route after oral administration.

At vancomycin serum concentrations of 10 to 100 mg/L, vancomycin is approximately 55% serum protein bound. After I.V. administration of vancomycin HCl, inhibitory concentrations are present in pleural, pericardial, ascitic and synovial fluids. Vancomycin does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs.

## TOXICOLOGY

### Acute Toxicity

The acute toxicity of vancomycin was evaluated in the rat, mouse and dog. Table 9 provides the LD<sub>50</sub> values obtained in these animals after administering vancomycin by various routes.

| <b>Table 9</b>   |            |              |            |
|--|------------|--------------|------------|
| <b>LD<sub>50</sub> (mg/kg) of Vancomycin in the rat, mouse and dog</b> |            |              |            |
| <b>Route of Administration</b>   | <b>Rat</b> | <b>Mouse</b> | <b>Dog</b> |
| Intravenous  | 319 ± 14   | 489 ± 41     | 292 ± 29   |
| Intraperitoneal  | 2218 ± 240 | 1734 ± 227   | --         |
| Subcutaneous   | --         | > 5000       | --         |
| Oral   | --         | > 5000       | --         |

In rats and mice following I.V. vancomycin, death resulted quickly from clonic convulsions, being a direct CNS effect. Following s.c. administration, no deaths were observed in rats, but extensive necrosis and sloughing of the subcutaneous tissue was observed. No death was observed in mice after oral administration, even at doses of 5 mg/kg. Death in dogs resulted generally from kidney failure, several days after drug administration. Vancomycin, when administered intravenously in a 5% solution to dogs at a rate of 0.6 mL/min., caused a slight dose-related drop in blood pressure. When the same dogs were given the same doses at a rate of 15 mL/min., blood pressure dropped dramatically, as much as 40%. This effect appears to be a histaminergic response.

### Subacute Toxicity

Dogs were given a daily I.V. dose of vancomycin at 12.5 mg and 50 mg/kg for 21 to 311 days. In 4 of 22 dogs receiving 50 mg/kg/day, slight renal damage was observed.

Monkeys tolerated I.V. doses of 25 to 50 mg/kg/day for 16 to 178 days, with irritation at the injection site as the only toxic effect.

No systemic toxicity was observed in cats receiving I.V. doses of 25 and 50 mg/kg/day for three months.

Doses of 150 mg vancomycin or 60 mg tobramycin given to rats resulted in no nephrotoxicity, however, when these agents were co-administered, significant renal toxicity occurred.

## REFERENCES

1. AHFS Drug Information. American Society of Hospital Pharmacists Inc., Bethesda, MD, USA 1994: 357-359
2. Barna, JCJ, Williams DH. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. *Am Rev microbial* 1984; 38: 339-357
3. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. *Rev. Infect. Dis* 1984; 6 (Suppl I): S235-41
4. Benner EJ, Morthland V. Methicillin-resistant *Staphylococcus aureus*. *N. Engl. J. Med* 1967; 227:676
5. Bunke CM, Aronoff GR et al. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. *Clin Pharmacol Ther* 1983; 34: 631
6. Cantu TG, Yamanake-uen NA et al. Serum vancomycin concentrations: reappraisal of their clinical value. *Clin. Infect Dis* 1994; 18: 533-543
7. Cooper GL, Given DB. Vancomycin, a comprehensive review of 30 years of clinical experience. Park Row Publishers, Inc. March 1986
8. Dudley, MN, Quintiliani R et al. Absorption of vancomycin. *Ann Intern Med* 1984; 104: 144
9. Geraci JE, Heilman ER et al. Antibiotic therapy of bacterial endocarditis VII. Vancomycin for acute micrococcal endocarditis. *Proc Staff Meet Mayo Clin* 1958;33: 172
10. Geraci JE, Heilman ER. Vancomycin in the treatment of staphylococcus endocarditis. *Proc. Staff Meet Mayo Clin* 1960; 35: 316
11. Gilbert DN, Wood CA et al. Failure of treatment with teicoplanin at 6 mg/kg/day in patients with *Staphylococcus aureus* intravascular infections. The infectious disease consortium of Oregon. *Antimicrob Agents Chemother* 1991; 35 (Iss1): 79-87
12. Griffith RS. Vancomycin: Continued clinical studies. In: *Antibiotics Annual New York. 1956-1957; Medical Encyclopedia*, pp. 118-122
13. Guay DR, Vance-Bryan K et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. *J. Clin Pharmacol* 1993; 33: 918-922
14. Kavanagh, KT, McCabe BF. Ototoxicity of oral neomycin and vancomycin. *Laryngoscope* 1983; 93: 649-653
15. Kirby WMM, Divelbiss CL. Vancomycin, clinical and laboratory studies. In: *AntibioticsAnnual. New york. 1956-1957; Medical Encyclopedia*, pp. 107-117

## REFERENCES (cont.)

16. Kirby WMM. Vancomycin therapy of severe staphylococcal infections. *J Antimicrob Chemother* 1984; 14 (Suppl D): 73-78
17. Kirby WMM. Vancomycin therapy in severe staphylococcal infections. *Rev. Infect Dis* 1981; 3 (Suppl): S236-239
18. Krogstad DJ, Moellering RC et al. Single-dose kinetics of intravenous vancomycin. *J Clin Pharmacol* 1980; 20: 197
19. Moellering RC Jr, Krogstad DJ et al. Vancomycin therapy in patients with impaired renal function; a nomogram for dosage. *Ann Intern Med* 1981; 94: 343
20. Moellering RC. Pharmacokinetics of vancomycin. *J Antimicrob Chemother* 1984; 14 (Suppl D): 43-52
21. Mogg GAG, Keighley MRB et al. Antibiotic-associated colitis – a review of 66 cases. *Br J Surg* 1979; 66: 738-742
22. National Committee for Clinical Laboratory Standards, M100-S5. Performance standards for antimicrobial disk susceptibility tests. NCCLS M100-S5, Vol. 14, No. 16. Villanova PA 1994
23. National Committee for Clinical Laboratory M7-T. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS, Villanova, PA; 1983
24. Pancorbo S, Conty C. Peritoneal transport of vancomycin in four patients undergoing continuous ambulatory peritoneal dialysis. *Nephron* 1982; 31: 37
25. Pauly DJ, Musa DM et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. *Pharmacotherapy* 1990; 10: 378-382
26. Redfield DC et al. Cerebrospinal fluid penetration of vancomycin. In: Nelson JD, Grassi C (eds.); *Current chemotherapy and infectious disease. Proc. 11<sup>th</sup> Int. Congr Chemotherapy and 19<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology* 1980; 1: 638-640
27. Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. *Burns* 1992; 18: 365-361
28. Romanelli VA, Howie MB et al. Intraoperative and postoperative effects of vancomycin administration in cardiac surgery patients: a prospective, double-blind, randomized trial. *Crit Care Med* 1993; 21 (ISS8): 1124-1131
29. Santre C, Leroy O et al. Pharmacokinetics of vancomycin during continuous hemodialysis. *Intensive Care Med* 1993; 19: 347-350

## REFERENCES (cont.)

30. Sato K, Lin TY et al. Bacteriological efficacy of mafeillin and vancomycin alone or in combination with rifampicin or amikacin in experimental meningitis due to methicillin-susceptible or – resistant *Staphylococcus aureus*. Jap J Antibiot 1985; 38: 145-152
31. Sheldrick GM, Jones PG et al. Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine. Nature 1978; 271: 223-225
32. Silva J, Batts DH et al. Treatment of *Clostridium difficile* colitis and diarrhea with vancomycin. Am J. Med 1981; 71: 815-821
33. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985; 16: 235-241
34. USPDI Drug Information for the Health Care Professional. United States Pharmacopeial Convention, Inc. Rockville, MD, USA 1995;1: 2755-2758
35. Watanakunakom C, Glotzbecker C. Enhancements of the effects of antistaphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother 1974; 6: 802
36. Watanakunakom C, Glotzbecker C. Synergism with aminoglycosides of penicillin, ampicillin and vancomycin against nonenterococcal group D Streptococci and viridans streptococci. J med Microb 1977; 10: 133
37. Wold JS, Turnipseed SA. Toxicology of vancomycin in laboratory animals. Rev Infect Dis 1981; 3 (Suppl): 224
38. Daljani A, Bisno A et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1990; 264: 2919-2922
39. Product Monograph: Sterile Vancomycin Hydrochloride USP, Hospira Healthcare Corporation, Town of Mount Royal, Quebec, March 12, 2004